skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Dyslipidemia is an increase or decrease in lipid levels from defined normal parameters and a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality. With a number of key brands used to treat Dyslipidemia facing patent expiration, statin and ezetimibe markets continue to face increasing genericization and the uptake of expensive add-on therapies is expected to spur growth of the Dyslipidemia market. Informa Pharma Intelligence forecasts total antidyslipidemic sales revenues to increase in the US, Japan, and five major EU markets. Datamonitor Healthcare forecasts sales from the US dyslipidemia market as remaining the most lucrative, rising to $22.3bn in 2025. Using the real-time development, pipeline event and impact tracking, and in-depth disease and market landscape reports from Informa Pharma Intelligence products Datamonitor Healthcare and Biomedtracker, this webinar will look at the market dynamics, opportunities, threats from substitutes and payer pressures for marketed drugs, and the likelihood of approval for late-phase pipeline drugs for the Dyslipidemia market. Other points to include in webinar summary:

  • Uptake of expensive add-on therapies is expected to spur growth of the dyslipidemia market.
  • An ability to secure positive CVOT results will play a pivotal role in the reimbursement of PCSK9 inhibitors Repatha and Praluent
  • Reduced cost, favorable dosing regimen, and strong efficacy of inclisiran will result rapid uptake of the medication.
  • The FDC of bempedoic acid and ezetimibe is anticipated to account for the majority of bempedoic acid franchise sales.
  • The statin and ezetimibe markets will continue to face increasing genericization over the forecast period.
  • Datamonitor Healthcare forecasts sales from the US dyslipidemia market will remain the most lucrative and rise to $22.3bn in 2025.

Watch webinar recording


Read also


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: